Clinical Trials

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT07214779 2026-03-16

MAESTRA 2

Phase 3 Recruiting

466 enrolled

Ovarian Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

40 enrolled

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

86 enrolled 17 charts

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

600 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Ovarian Neoplasms

NCT05567601 2025-06-05

Doxil/Caelyx BE Study

BreastGynecologicPlasma cellSarcoma

36 enrolled

AIDS-related Kaposi sarcoma, Breast Neoplasms, Multiple Myeloma, Ovarian Neoplasms

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

77 enrolled 9 charts

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1/2 Terminated

10 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03596281 2024-10-18

PEMBOV

47 enrolled

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

120 enrolled 22 charts

Ovarian Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

35 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01279291 2024-04-26

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Phase 1 Terminated

22 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04814875 2024-02-14

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Phase 1/2 Terminated

16 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02584478 2023-11-08

AL3818

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01705158 2023-09-06

MYCA

Phase 1/2 Completed

87 enrolled

Ovarian Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

566 enrolled 40 charts

Ovarian Neoplasms

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

820 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT03639246 2023-02-13

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

53 enrolled

Ovarian Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Ovarian Neoplasms

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Phase 1 Terminated

11 enrolled

Ovarian Neoplasms

NCT01379989 2022-02-09

INOVATYON

617 enrolled

Ovarian Neoplasms

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1/2 Terminated

22 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01170650 2021-09-30

PROCEED

Phase 3 Terminated

441 enrolled

Neoplasms, Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Ovarian Neoplasms

NCT02903004 2021-08-25

MITO23

242 enrolled

Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

442 enrolled 33 charts

Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Classical hematologyGynecologic

97 enrolled 22 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02751918 2019-11-22

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

65 enrolled

Ovarian Neoplasms

NCT00846612 2019-09-30

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

15 enrolled

Ovarian Neoplasms, Recurrence

NCT00913835 2019-09-26

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

125 enrolled 20 charts

Neoplasms, Ovarian Neoplasms

NCT01459380 2019-07-22

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

41 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

581 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

16 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01358071 2018-09-27

NGR018

119 enrolled

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01113957 2018-06-06

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

168 enrolled